118 filings
8-K
VSTM
Verastem Inc
9 Apr 24
Delivering Novel Therapies in RAS/MAPK Pathway Driven Cancers April 2024 Corporate Presentation
5:10pm
8-K
VSTM
Verastem Inc
29 Jan 24
Regulation FD Disclosure
4:01pm
8-K
VSTM
Verastem Inc
19 Jan 24
Submission of Matters to a Vote of Security Holders
7:54am
8-K
VSTM
Verastem Inc
8 Jan 24
Entry into a Material Definitive Agreement
4:02pm
8-K
VSTM
Verastem Inc
27 Oct 23
Departure of Directors or Certain Officers
4:41pm
8-K
xcy9x zil9p
28 Sep 23
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
2:27pm
8-K
pnqh 8gvkgs3s3h
12 Sep 23
Corporate Presentation September 2023
4:08pm
8-K
pkeq5exf53z1u82dx2
4 Aug 23
Departure of Directors or Certain Officers
4:40pm
8-K
safldoe6am
12 Jul 23
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
8:50am
8-K
jx7vj7ib
21 Jun 23
Other Events
7:00am
8-K
uufbaey68lc0
8 Jun 23
Corporate Presentation June 2023
5:24pm
8-K
bget4pkv
31 May 23
Verastem Oncology Announces Reverse Stock Split
9:25am
8-K
yg9vmav9yox7 x3
25 May 23
Data Build on Breakthrough Therapy Designation of the Combination of Avutometinib and Defactinib in Low-Grade Serous Ovarian Cancer
5:18pm
8-K
8s3hsifl mxc2a1eqb
16 May 23
Submission of Matters to a Vote of Security Holders
7:26am
8-K
k800g 7drurs52jaj0e
27 Mar 23
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:30pm
8-K
2401jsx
13 Mar 23
Regulation FD Disclosure
6:04am
8-K
1daf4sol9
2 Feb 23
Results of Operations and Financial Condition
7:00am
8-K
ypjdi50l
25 Jan 23
Entry into a Material Definitive Agreement
8:18am
8-K
2593vqq0u6
24 Jan 23
Regulation FD Disclosure
5:29pm
8-K
5n7jl2
15 Dec 22
Verastem Oncology Appoints Rob Gagnon to Board of Directors
5:10pm